Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Frequency Therapeutics was a clinical-stage biotechnology company that aimed to develop a new class of regenerative medicine. Their primary research focused on activating progenitor cells within the body to repair or reverse damage from degenerative diseases, with a lead program targeting sensorineural hearing loss (SNHL). After its lead candidate FX-322 failed to meet primary endpoints in a Phase 2b study in early 2023, the company discontinued its hearing loss programs, underwent significant restructuring, and subsequently completed a reverse merger with Korro Bio in November 2023. The combined entity operates as Korro Bio. This information reflects Frequency Therapeutics as an entity prior to these conclusive events.
The headquarters served as the main center for the company's research and development activities, clinical trial management, and corporate operations.
Situated within the Hayden Research Campus, the facility likely comprised modern laboratory spaces, R&D infrastructure, and corporate offices suitable for a clinical-stage biotech company.
Prior to its strategic pivot and merger, Frequency Therapeutics likely fostered a science-driven, innovative, and collaborative work environment focused on translational research and addressing unmet medical needs. The culture would have experienced significant shifts during the 2023 restructuring and merger process.
Its location in Lexington provided strategic proximity to a dense ecosystem of academic institutions, research talent, and other life science companies, facilitating collaborations and recruitment.
Frequency Therapeutics' global activities were primarily centered around its clinical trial operations for its therapeutic candidates. These trials involved sites in the United States and select countries in Europe. The company did not maintain significant independent international offices for corporate or R&D functions, which were centralized at its U.S. headquarters.
75 Hayden Avenue
Lexington
MA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Frequency Therapeutics' leadership includes:
Frequency Therapeutics has been backed by several prominent investors over the years, including:
The period leading up to and including Frequency Therapeutics' merger with Korro Bio in November 2023 saw a complete transition of its executive leadership. Following the merger, the Frequency Therapeutics executive team departed, and the combined company proceeded under Korro Bio's leadership. This was preceded by strategic restructuring in early 2023.
Discover the tools Frequency Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its merger and operational cessation, Frequency Therapeutics likely used standard corporate email address formats. A common pattern in the industry is [first_initial][last]@[companydomain.com].
[first_initial][last]@frequencytx.com
Format
jdoe@frequencytx.com
Example
0%
Success rate
Korro Bio / PR Newswire • November 14, 2023
Korro Bio, Inc. and Frequency Therapeutics, Inc. announced the successful completion of their merger. The combined company now operates as Korro Bio, Inc., trading on Nasdaq under 'KRRO', and will focus on advancing Korro's RNA editing pipeline....more
Frequency Therapeutics / GlobeNewswire • July 17, 2023
Frequency Therapeutics entered into a definitive merger agreement with Korro Bio. The transaction aimed to combine Frequency's resources with Korro's RNA editing platform, with the new entity to operate as Korro Bio....more
Frequency Therapeutics / GlobeNewswire • February 13, 2023
Frequency Therapeutics reported that its FX-322 candidate for acquired sensorineural hearing loss did not meet its primary efficacy endpoint in a Phase 2b study. As a result, the company discontinued the hearing loss program and initiated a strategic review, including workforce reductions....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Frequency Therapeutics, are just a search away.